Overview

The development of targeted therapy is an important advancement in cancer treatment. This session will review the application of next generation sequencing in oncology and compare testing methods. Participants will explore oncogenic driver mutations and FDA-approved targeted therapies in non-small cell lung cancer, along with management approaches for toxicities related to tyrosine kinase inhibitors. 

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Explain the basic scientific principles used in next generation sequencing (NGS) and its application in oncology to identify relevant variants or mutations

2. Describe tissue-based and ctDNA testing methods and the advantages and disadvantages of each 

3. Discuss the Non-Small Cell Lung Cancer (NSCLC) mutations with FDA approved therapies within the NSCLC treatment landscape

4. Recognize the diagnosis and management of commonly encountered toxicities for select Tyrosine Kinase Inhibitors (TKIs)